The effects of weekly administration of 40 mg pegvisomant or placebo on quality of life and insulin sensitivity in acromegalic patients with normal IGF-I [insulin-like growth factor-I] concentrations during long-term treatment with long-acting somatostatin analogs

Trial Profile

The effects of weekly administration of 40 mg pegvisomant or placebo on quality of life and insulin sensitivity in acromegalic patients with normal IGF-I [insulin-like growth factor-I] concentrations during long-term treatment with long-acting somatostatin analogs

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Oct 2009

At a glance

  • Drugs Pegvisomant (Primary)
  • Indications Acromegaly
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top